ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
ed in different studies classified as: duodenal carcinoid; duodenal gastroenteropancreatic (GEP) tumor; duodenal pancreatic neuroendocrine tumor (p-NET); duodenal gastrinoma; duodenal somatostatinoma; gangliocytic paraganglioma; ampullary carcinoid or somatostatinoma; argentaffin carcinoid-producing serotonin of the duodenum; psammomatous somatostatinoma; duodenal NE carcinoma, poorly differentiated and small-cell NE carcinoma of the duodenum [6] . The clinical and management aspect of duodenal gastrinomas are included in the ‘Endocrine Tumors of the Pancreas – Gastrinoma’ section and duodenal gastrinomas will only be considered in this section in comparison with the other d-NENs. Introduction Gastric neuroendocrine neoplasms (g-NENs) [1] are increasingly recognized due to expanding indications of upper gastrointestinal (UGI) endoscopy. Often silent and benign, g-NENs may, however, be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Duodenal neuroendocrine tumors (d-NENs) [2] may or may not be associated with a functional clinical syndrome. The term d-NEN includes all duodenal tumors with neuroendocrine (NE) features as determined by histological/immunohistochemical methods including positivity for NE cytosolic markers (neuron-specific enolase (NSE), PGP 9.5) or secretory vesicle proteins (chromogranin A (CgA), synaptophysin) and also frequently the presence of specific gastrointestinal (GI) hormones [3–8] . The term d-NEN in this paper refers to tumors includ- Published online: February 15, 2012 Gianfranco Delle Fave Digestive and Liver Disease Unit ‘Sapienza’ University of Rome, Sant’Andrea Hospital Via Di Grottarossa 1035–1039, IT–00189 Rome (Italy) Tel. +39 06 3377 5691, E-Mail gianfranco.dellefave @ uniroma1.it © 2012 S. Karger AG, Basel 0028–3835/12/0952–0074$38.00/0 Accessible online at: www.karger.com/nen 1
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These tumors develop as a consequence of the parietal cell loss, which leads to reduced gastric acid secretion and downstream persistent hypergastrinemia, enterochromaffin-like cell (ECL) hyperplasia, and, in a small percentage, ECL dysplasia and gastric NETs.27”
From AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021) · cites this paper as [27]
Citations
Cites
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & HARMON, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2157::aid-cncr2820730821>3.0.co;2-1 · Cited by 2,135
(2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Paraganglioma of the filum terminale internum
Kamalian, N., Abbassioun, K., Amirjamshidi, A., & Shams-Shahrabadi, M. (1987) · Journal of Neurology · doi:10.1007/bf00314201 · Cited by 1,594
Report of a case and review of the literature
Kamalian, N., Abbassioun, K., Amirjamshidi, A., et al. (1987) · Cited by 1,576
THE CLASSIFICATION OF CARCINOID TUMOURS
WILLIAMS, E. (1963) · The Lancet · doi:10.1016/s0140-6736(63)90951-6 · Cited by 885
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Self-citationThe Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification
KLÖPPEL, G., PERREN, A., & HEITZ, P. U. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.002 · Cited by 794
Histological Typing of Endocrine Tumours
Solcia, E., Klöppel, G., & Sobin, L. H. (2000) · Springer eBooks · doi:10.1007/978-3-642-59655-1 · Cited by 747
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Self-citation
Research works printed but not linked: 30
- Attanoos R, 1991, Semin Diagn Pathol, 8, 149
- Soga J, 1996, J Exp Clin Cancer Res, 15, 3
- Bordi C, 1999, Ital J Gastroenterol Hepatol, 31, S94
- Thomas RM, 1994, Cancer, 73, 2053, 10.1002/1097-0142(19940415)73:8<2053::aid-cncr2820730807>3.0.co;2-0 · DOI · Paper page
- Cattan D, 1991, Gastroenterol Clin Biol, 15, 30C
- Marignani M, 1999, Am J Gastroenterol, 94, 766
- Spinazzola AJ, 1963, Am Surg, 29, 405
- Walton GF, 1997, Am Surg, 63, 302
- Soga J, 1999, J Exp Clin Cancer Res, 18, 13
- Taccagni GL, 1986, Am J Gastroenterol, 81, 33
- Burke AP, 1990, Arch Pathol Lab Med, 114, 700
- Capella C, 1990, Hepatogastroenterology, 37, 247
- Heymann MF, 2004, Hepatogastroenterology, 51, 1367
- Soga J, 2003, J Exp Clin Cancer Res, 22, 349
- Thom AK, 1991, Surgery, 110, 1086
- Zogakis TG, 2003, Ann Surg, 238, 42
- Gibril F, 2004, Medicine, 83, 43, 10.1097/01.md.0000112297.72510.32 · DOI · Paper page
- Cohen T, 1981, Am J Gastroenterol, 75, 197
- Amano S, 1978, Acta Pathol Jpn, 28, 721
- Orbuch M, 1995, Karger, 23, 268
- Yoshikane H, 1995, Am J Gastroenterol, 90, 642
- Meijer WG, 2003, J Nucl Med, 44, 184
- Lebtahi R, 1999, J Nucl Med, 40, 1602
- Hubalewska-Dydejczyk A, 2005, Nucl Med Rev Cent East Eur, 8, 155
- Taal BG, 2005, Minerva Gastroenterol Dietol, 51, 335
- Sato T, 2005, Hepatogastroenterology, 52, 678
- Horsley GW, 1957, Surg Gynecol Obstet, 105, 417
- Thompson GB, 1985, Surgery, 98, 1054
- Yoshikane H, 1993, Gastrointest Endosc, 39, 375, 10.1016/s0016-5107(93)70109-1 · DOI
- Kwekkeboom DJ, 2005, J Nucl Med, 46, 62S
Cited by
AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review
Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.078 · Cited by 560
“These tumors develop as a consequence of the parietal cell loss, which leads to reduced gastric acid secretion and downstream persistent hypergastrinemia, enterochromaffin-like cell (ECL) hyperplasia, and, in a small percentage, ECL dysplasia and gastric NETs.(27) Based on longitudinal cohort studies, the incidence ra…”
BackgroundInfluentialFalconi, M., Bartsch, D. K., Eriksson, B., Klöppel, G., Lopes, J. M., O'Connor, J. M., Salazar, R., Taal, B. G., Vullierme, M. P., & O'Toole, D. (2012) · Neuroendocrinology · doi:10.1159/000335587 · Cited by 526
Self-citationENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms
Delle Fave, G., O''Toole, D., Sundin, A., Taal, B., Ferolla, P., Ramage, J. K., Ferone, D., Ito, T., Weber, W., Zheng-Pei, Z., et al. (2016) · Neuroendocrinology · doi:10.1159/000443168 · Cited by 495
Self-citationDeprez, P. H., Moons, L. M. G., OʼToole, D., Gincul, R., Seicean, A., Pimentel-Nunes, P., Fernández-Esparrach, G., Polkowski, M., Vieth, M., Borbath, I., et al. (2022) · Endoscopy · doi:10.1055/a-1751-5742 · Cited by 384
“In these cases, most guidelines recommend surveillance with repeat endoscopy every 1 – 2 years [72,75], and also for adenocarcinoma screening in the atrophic mucosa.”
BackgroundPanzuto, F., Ramage, J., Pritchard, D. M., van Velthuysen, M. F., Schrader, J., Begum, N., Sundin, A., Falconi, M., & O'Toole, D. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13306 · Cited by 180
Lahner, E., Zagari, R. M., Zullo, A., Di Sabatino, A., Meggio, A., Cesaro, P., Lenti, M. V., Annibale, B., & Corazza, G. R. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.09.016 · Cited by 187
S2k-Leitlinie Neuroendokrine Tumore: AWMF-Reg. 021-27
Authors, Collaborators:, Deutsche Gesellschaft für Gastroenterologie, V. U. S. (., (Patientenvertretung), N. N. T. (. E. V., (Patientenvertretung), B. S. N. T. E. V. (.-S., Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), U. A. I. O. (. D. D. K. E. V., (DGAV), D. G. F. A. U. V. E. V., (DGCH), D. G. F. C., (DGEBV), D. G. F. E. U. B. V., (DGNM), D. G. F. N. E. V., et al. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0604-2924 · Cited by 180
Review article: the investigation and management of gastric neuroendocrine tumours
Basuroy, R., Srirajaskanthan, R., Prachalias, A., Quaglia, A., & Ramage, J. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12698 · Cited by 180
“There are important epidemiological, pathophysiological, endoscopic and histological differences between each type that affects prognosis, management and follow-up.(7)”
BackgroundManagement of gastric and duodenal neuroendocrine tumors
Sato, Y., Hashimoto, S., Mizuno, K.-I., Takeuchi, M., & Terai, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6817 · Cited by 161
Coriat, R., Walter, T., Terris, B., Couvelard, A., & Ruszniewski, P. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0476 · Cited by 156
Self-citationA Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management
Sultana, Q., Kar, J., Verma, A., Sanghvi, S., Kaka, N., Patel, N., Sethi, Y., Chopra, H., Kamal, M. A., & Greig, N. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155138 · Cited by 158
de Mestier, L., Lepage, C., Baudin, É., Coriat, R., Courbon, F., Couvelard, A., Cao, C. D., Frampas, É., Gaujoux, S., Gincul, R., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.02.011 · Cited by 158
Self-citationRecurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
Genc, C., Falconi, M., Partelli, S., Muffatti, F., van Eeden, S., Doglioni, C., Klümpen, H., van Eijck, C. H. J., & van Dijkum, E. J. M. N. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6518-2 · Cited by 109
Singh, S., Asa, S. L., Dey, C., Kennecke, H. F., Laidley, D. T., Law, C., Asmis, T. R., Chan, D. L. H., Ezzat, S., Goodwin, R. A., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.05.003 · Cited by 108
“Whenever possible, minimally invasive techniques that preserve gastric volume and function should be applied [57].”
BackgroundGastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging
Baumann, T., Rottenburger, C., Nicolas, G., & Wild, D. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.01.003 · Cited by 107
Lahner, E., Esposito, G., Pilozzi, E., Purchiaroni, F., Corleto, V. D., Di Giulio, E., & Annibale, B. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1010570 · Cited by 97
“All patients underwent gastroscopy with three biopsies taken from the gastric antrum (within 3 cm of the pyloric ring, lesser and greater curve, anterior or posterior wall) and three biopsies from the midbody along the greater curve [15].”
MethodMetastatic type 1 gastric carcinoid: A real threat or just a myth?
Grozinsky‐Glasberg, S., Thomas, D., Strosberg, J. R., Pape, U.-F., Felder, S., Tsolakis, A. V., Alexandraki, K. I., Fraenkel, M., Saiegh, L., Reissman, P., et al. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8687 · Cited by 94
Fazio, N., & Milione, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.006 · Cited by 95
A current clinical overview of atrophic gastritis
Annibale, B., Esposito, G., & Lahner, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1718491 · Cited by 84
“scopy, surgery is only exceptionally indicated [17,132,133].”
BackgroundToumpanakis, C., & Caplin, M. E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.006 · Cited by 85
Current best practice in the management of neuroendocrine tumors
Tsoli, M., Chatzellis, E., Koumarianou, A. A., Kolomodi, D., & Kaltsas, G. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818804698 · Cited by 93
Management of Gastrointestinal Neuroendocrine Tumors
Wang, R., Zheng-Pywell, R., Chen, H. A., Bibb, J. A., Chen, H. R., & Rose, J. B. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419884058 · Cited by 83
GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE
Dias, A. R., Azevedo, B. C., Alban, L. B. V., Yagi, O. K., Ramos, M. F. K. P., Jacob, C. E., Barchi, L. C., Cecconello, I., Ribeiro, U., & Zilberstein, B. (2017) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-6720201700020016 · Cited by 89
Gastric and duodenal neuroendocrine tumours
O’Toole, D., Fave, G. D., & Jensen, R. T. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.01.002 · Cited by 76
“Endoscopic resection can be easily repeated provided tumours do not grow beyond T1 [3,96] and this strategy appears to be universally accepted Nonetheless, recurrences do occur and a recurrence rate in a recent series of patients treated endoscopically was 64% (21/33) at a median of eight months and of these, 67% (14/…”
BackgroundInfluentialGastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli, F., Zilli, A., Conte, D., Ciafardini, C., & Massironi, S. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1054426 · Cited by 73
Boyce, M. J., Moore, A. R., Sagatun, L., Parsons, B. N., Varró, A., Campbell, F., Fossmark, R., Waldum, H. L., & Pritchard, D. M. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13146 · Cited by 71
Sato, Y., Imamura, H., Kaizaki, Y., Koizumi, W., Ishido, K., Kurahara, K., Suzuki, H., Fujisaki, J., Hirakawa, K., Hosokawa, O., et al. (2013) · Digestive Endoscopy · doi:10.1111/den.12197 · Cited by 69
Long-term results of endoscopic resection for type I gastric neuroendocrine tumors
Uygun, A., Kadayifci, A., Polat, Z., Yilmaz, K., Gunal, A., Demir, H., & Bagci, S. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23477 · Cited by 62
“conservative management of Type 1 gastric carcinoids based on endoscopic follow‐up or endoscopic lesion resection [18].”
BackgroundPezzilli, R., Partelli, S., Cannizzaro, R., Pagano, N., Crippa, S., Pagnanelli, M., & Falconi, M. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.10.001 · Cited by 61
A rare rarity: Neuroendocrine tumor of the esophagus
Giannetta, E., Guarnotta, V., Rota, F., de Cicco, F., Grillo, F., Colao, A., & Faggiano, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.012 · Cited by 61
Grozinsky‐Glasberg, S., Alexandraki, K., Angelousi, A. G., Chatzellis, E., Sougioultzis, S., & Kaltsas, G. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.04.013 · Cited by 60
Campana, D., Ravizza, D., Ferollà, P., Faggiano, A., Grimaldi, F., Albertelli, M., Berretti, D., Castellani, D., Cacciari, G., Fazio, N., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0584-z · Cited by 51
Self-citationKnigge, U., & Hansen, C. P. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.12.005 · Cited by 52
Self-citationEndoscopic diagnosis and management of type I neuroendocrine tumors
Sato, Y. (2015) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v7.i4.346 · Cited by 48
Management of Gastric Neuroendocrine Tumors: A Review
Sok, C., Ajay, P. S., Tsagkalidis, V., Kooby, D. A., & Shah, M. M. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14712-9 · Cited by 50
“6,27,31 In these cases where surgery is indicated, the North American Neuroendocrine Tumor Society (NANETS) recommends tumor excision via wedge resection.”
Berković, M. C., Čaćev, T., Ivković, T. C., Zjačić-Rotkvić, V., & Kapitanović, S. (2014) · Neuroendocrinology · doi:10.1159/000362339 · Cited by 47
Chung, C., Tsai, C.-L., Chu, Y., Chen, K., Lin, J., Chen, B., Sun, W., Yen, H., Chen, C., Wu, I., et al. (2018) · Medicine · doi:10.1097/md.0000000000012101 · Cited by 50
Gastric neuroendocrine neoplasms: A review
Köseoğlu, H., Düzenli, T., & Sezikli, M. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i27.7973 · Cited by 45
Massironi, S., Zilli, A., Fanetti, I., Ciafardini, C., Conte, D., & PERACCHI, M. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.07.155 · Cited by 43
Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors
Chin, J. L., & O’Toole, D. (2017) · Clinical Endoscopy · doi:10.5946/ce.2017.181 · Cited by 41
“Management of gastric neuroendocrine tumors It has been well-recognised that treatment of g-NETs depends on the subtype, even when the disease has metastasized.(18,19,29) The grade of g-NETs are classified into 3 categories (not to be confused with the subtype) depending on two measures: the mitotic rate reported by t…”
BackgroundMethodInfluentialDuodenal neuroendocrine neoplasms: a still poorly recognized clinical entity
Rossi, R. E., Rausa, E., Cavalcoli, F., Conte, D., & Massironi, S. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1468479 · Cited by 38
“In those cases of advanced metastatic disease not suitable for any treatment, the patients should be re-evaluated every 3–6 months by CgA, imaging test (CT or ultrasound) and nuclear medicine imaging, whilst for the patients with metastatic/inoperable disease receiving anti-tumor treatment, follow-up may change accord…”
BackgroundMethodInfluentialPoleé, I. N., Hermans, B. C. M., van der Zwan, J. M., Bouwense, S. A. W., Dercksen, M. W., Eskens, F. A. L. M., Havekes, B., Hofland, J., Kerkhofs, T. M. A., Klümpen, H., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.003 · Cited by 41
Gastroenteropancreatic Neuroendocrine Tumors
Fernandes, C. J., Leung, G., Eads, J. R., & Katona, B. W. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2022.06.002 · Cited by 38
Castoro, C., Moli, R. L., Arpi, M. L., Tavarelli, M., Sapuppo, G., Frittitta, L., Squatrito, S., & Pellegriti, G. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0445-5 · Cited by 36
“GC type 1 arise in achlorhydria secondary to (autoimmune) atrophic fundic gastritis, while type 2 develop in response to hypergastrinemia resulting from neoplastic secretion from gastrinomas (Zollinger–Ellison Syndrome), mostly in patients presenting with multiple endocrine neoplasia type 1 (MEN 1) [26, 27].”
BackgroundSurgical management of neuroendocrine tumors
Tamburrino, D., Spoletini, G., Partelli, S., Muffatti, F., Adamenko, O. M., Crippa, S., & Falconi, M. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.10.003 · Cited by 32
Min, B., Kim, E. R., Lee, J. H., Kim, K., Min, Y. W., Rhee, P., Kim, J. J., & Rhee, P. (2013) · Digestion · doi:10.1159/000349958 · Cited by 32
Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms
Attili, F., Capurso, G., Vanella, G., Fuccio, L., Fave, G. D., Costamagna, G., & Larghi, A. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.04.007 · Cited by 33
Lipiński, M., Rydzewska, G. M., Fołtyn, W., Andrysiak-Mamos, E., Bałdys‐Waligórska, A., Bednarczuk, T., Blicharz-Dorniak, J., Bolanowski, M., Boratyn-Nowicka, A., Borowska, M., et al. (2017) · Endokrynologia Polska · doi:10.5603/ep.2017.0016 · Cited by 34
“The division according to the proliferation index (Ki-67 > 55%) has clinical consequences for the response to chemotherapy (ChTx) and prognosis: NECs with Ki-67 > 55% demonstrated better response to platin-based ChTx, although the median survival was four months shorter than NETs G3 with lower proliferation index valu…”
Backgroundon behalf of NIKE group, Guarnotta, V., Martini, C., Davì, M. V., Pizza, G., Colao, A. A. L., & Faggiano, A. (2017) · Endocrine · doi:10.1007/s12020-017-1420-4 · Cited by 33
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy—A literature review
Berardi, R., Rinaldi, S., Torniai, M., Morgese, F., Partelli, S., Caramanti, M., Onofri, A., Polenta, V., Pagliaretta, S., Falconi, M., et al. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.003 · Cited by 33
Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms?
Exarchou, K., Kamieniarz, L., Tsoli, M., Victor, A., Oleinikov, K., Khan, M. S., Srirajaskanthan, R., Mandair, D., Grozinsky‐Glasberg, S., Kaltsas, G., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02775-1 · Cited by 31
Gastric cancer in patients with type I gastric carcinoids
Lahner, E., Esposito, G., Pilozzi, E., Galli, G., Corleto, V. D., Giulio, E. D., & Annibale, B. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0393-8 · Cited by 33
“5 cm in diameter or suspected incomplete resection, endoscopic ultrasonography (EUS) was performed after sedation by intravenous propofol using a Pentax EG-3630UR endoscope to assess the polyp’s complete removal and to exclude lymph nodal involvement [1].”
BackgroundMethodCurrent concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms
Kaltsas, G., Grozinsky‐Glasberg, S., Alexandraki, K., Thomas, D., Tsolakis, A. V., Gross, D., & Grossman, A. B. (2014) · Clinical Endocrinology · doi:10.1111/cen.12476 · Cited by 32
Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors
Maxwell, J. E., O’Dorisio, T. M., & Howe, J. R. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.08.008 · Cited by 32
Iwasaki, T., Nara, S., Kishi, Y., Esaki, M., Shimada, K., & Hiraoka, N. (2016) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-016-1537-6 · Cited by 31
Management of gastric neuro-endocrine tumours in a large French national cohort (GTE)
Manfrédi, S., Walter, T., Baudin, É., Coriat, R., Ruszniewski, P. B., Lecomte, T., Laurenty, A.-P., Goichot, B., Rohmer, V., Roquin, G., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1355-9 · Cited by 32
Self-citationKoffas, A., Giakoustidis, A. E., Papaefthymiou, A., Bangeas, P., Giakoustidis, D. E., Papadopoulos, V. N., & Toumpanakis, C. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2023.1064145 · Cited by 33
“Some dNENs, such as gastrinomas causing ZES, may be missed on both conventional endoscopy and EUS, and these are diagnosed by hormone assays as described in detail in a previous section (108).”
BackgroundPotential clinical indications for a CCK2 receptor antagonist
Boyce, M. J., Lloyd, K., & Pritchard, D. M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.09.002 · Cited by 29
Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors
Chi, W., Warner, R. R. P., Chan, D. L. H., Singh, S., Segelov, E., Strosberg, J., Wisnivesky, J. P., & Kim, M. K. (2018) · Pancreas · doi:10.1097/mpa.0000000000001005 · Cited by 29
Carvão, J., Dinis-Ribeiro, M. J., Pimentel‐Nunes, P., & Libânio, D. (2021) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000512089 · Cited by 32
Nishio, M. (2020) · Annals of Gastroenterology · doi:10.20524/aog.2020.0477 · Cited by 28
“Therefore, several guidelines recommend endoscopic resection, rather than significantly more invasive open surgery, for duodenal NETs ≤10 mm in diameter and confined to the submucosal layer, with no evidence of lymph node or distant metastasis on CT [4,5,27,28].”
BackgroundSurgical treatment for gastrointestinal neuroendocrine tumors
Eto, K., Yoshida, N., Iwagami, S., Iwatsuki, M., & Baba, H. A. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12396 · Cited by 28
Alessandrino, F., Ivanovic, A. M., Yee, E. U., Radulovic, D., Souza, D., & Mortelé, K. J. (2015) · Abdominal Imaging · doi:10.1007/s00261-015-0528-3 · Cited by 27
“well-differentiated neuroendocrine tumors, previously referred to as carcinoids and generally considered benign; (2) intermediate-grade, well-differentiated neuroendocrine tumors; and (3) high-grade, poorly differentiated neuroendocrine carcinomas [43, 44].”
BackgroundLahner, E., Pilozzi, E., Esposito, G., Galli, G., & Annibale, B. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.878381 · Cited by 27
“Type III GCs were accurately staged and treated with total gastrectomy, according to the ENETS Guidelines [3].”
BackgroundMethodInfluentialCanakis, A., & Lee, L. S. (2022) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v14.i5.267 · Cited by 28
Dasari, B. V. M., Al-Shakhshir, S., Pawlik, T. M., Shah, T., Marudanayagam, R., Sutcliffe, R. P., Mirza, D. F., Muiesan, P., Roberts, K. J., & Isaac, J. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3825-7 · Cited by 26
Alexandraki, K., Nikolaou, A., Thomas, D., Syriou, V., Korkolopoulou, P. A., Sougioultzis, S., & Kaltsas, G. (2013) · Clinical Endocrinology · doi:10.1111/cen.12346 · Cited by 27
Management of Duodenal Neuroendocrine Tumors: Surgical versus Endoscopic Mucosal Resection
Tran, C. G., Sherman, S. K., Suraju, M. O., Nayyar, A., Gerke, H., Abiad, R. G. E., Chandrasekharan, C., Ear, P. H., O’Dorisio, T. M., Dillon, J. S., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10774-9 · Cited by 25
Chin, J. L., O'Connell, J. E. A., Muldoon, C., Swan, N., Reynolds, J. V., Ravi, N., Geoghegan, J., Conlon, K. C., O'Shea, D. B., & O’Toole, D. (2020) · Digestive Surgery · doi:10.1159/000510962 · Cited by 27
Laffi, A., Lania, A. G., Ragni, A., Vito, V. D., Liccardi, A., Rubino, M., Sesti, F. F., Colao, A. A. L., Faggiano, A., & on behalf of the NIKE Group (2023) · Cancers · doi:10.3390/cancers15082202 · Cited by 27
Mandair, D., Kamieniarz, L., Pizanias, M., Weickert, M. O., Narayan, A. R., O’Mahony, L. F., Caplin, M. E., Ramage, J. K., Prachalias, A. A., Srirajaskanthan, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19738-9 · Cited by 22
Grimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Papini, E., Angelini, F., Baldelli, R., Berretti, D., Bianchetti, S., Bizzarri, G., et al. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0119-0 · Cited by 23
“In patients with local advanced neoplasm and/or liver metastases, bone scan and MRI of spine and pelvis should be performed [153].”
BackgroundSelf-citationGIPR expression in gastric and duodenal neuroendocrine tumors
Sherman, S. K., Maxwell, J. E., Carr, J. C., Wang, D., O'Dorisio, M. S., O’Dorisio, T. M., & Howe, J. R. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.01.044 · Cited by 22
“workup, and operative management is usually warranted [4].”
BackgroundMethodInfluentialNeuroendocrine neoplasms of the stomach
Louthan, O. (2013) · Biomedical Papers · doi:10.5507/bp.2013.045 · Cited by 22
“For comparison, previous WHO from 2000 classified endocrine neoplasms (1) into well-differentiated neuroendocrine tumours (= G1), (2) well-differentiated endocrine carcinomas (= G2), (3) poorly-differentiated endocrine carcinoma/small cell carcinomas (= G3) (ref.”
MethodMidgut neuroendocrine tumor presenting with acute intestinal ischemia
Mantzoros, I., Savvala, N. A., Ioannidis, O., Parpoudi, S., Loutzidou, L., Kyriakidou, D., Cheva, A., Intzos, V., & Tsalis, K. G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i45.8090 · Cited by 22
Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms
Huang, P., Tsai, K., Liang, C., Tai, W., Rau, K., Wu, K., Huang, C., & Chuah, S. (2018) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2018.05.009 · Cited by 22
Gastric Mixed Adenoneuroendocrine Carcinoma with a Good Prognosis
Fukuba, N., Yuki, T., Ishihara, S., Sonoyama, H., Tada, Y., Kusunoki, R., Oka, A., Oshima, N., Moriyama, I., Kawashima, K., et al. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.3328 · Cited by 21
“Gastric NETs are comprised of three distinct tumor types: type I, associated with autoimmune chronic atrophic gastritis; type II, associated with multiple endocrine neoplasia type 1 (MEN1) and Zollinger-Ellison syndrome; and type III, which are sporadic (2).”
BackgroundLv, Y., Han, X., Xu, X., Ji, Y., Zhou, Y., Sun, H., Zhou, J., Fan, J., Lou, W., & Huang, C. (2019) · BMC Cancer · doi:10.1186/s12885-019-5457-z · Cited by 21
Somatostatin analogs for gastric carcinoids: For many, but not all
Massironi, S., Zilli, A., & Conte, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6785 · Cited by 25
Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management
Schizas, D., Mastoraki, A. T., Kirkilesis, G. I., Sioulas, A. D., Papanikolaou, I. S., Misiakos, E. P., Arkadopoulos, N. F., & Liakakos, T. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-017-9978-x · Cited by 20
Wang, R., Mohapatra, S., Jovani, M., Akshintala, V. S., Kamal, A., Brewer, O. G., Kumbhari, V., Shin, E. J., Canto, M. I., Khashab, M. A., et al. (2021) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.12.012 · Cited by 20
Cavallaro, A. S., Zanghì, A., Cavallaro, M., Menzo, E. L., Carlo, I. D., Vita, M. D., Cardì, F., Piccolo, G., Mattia, P. D., & Cappellani, A. (2014) · International Journal of Surgery · doi:10.1016/j.ijsu.2014.05.017 · Cited by 20
Intervention in gastro-enteropancreatic neuroendocrine tumours
Baudin, É., Planchard, D., Scoazec, J., Guigay, J., Dromain, C., Hadoux, J., de Baère, T., Elias, D. M., & Ducreux, M. P. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.01.008 · Cited by 18
“mortality rate of the surgery is expected to be above 1%, like in patients with a sporadic or inherited pancreatic NET localized in the head of the pancreas [63,70].”
BackgroundClinicopathological features and prognostic validity of WHO grading classification of SI-NENs
Chen, L., Zhou, L., Zhang, M., Shang, L., Zhang, P., Wang, W., Cheng, F., Li, J., Xu, T., Tan, H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3490-3 · Cited by 18
“The heterogeneities between duodenal and jejunal/ileal NENs indicated that NENs in these two locations might have different biological behaviors which should be managed differently [17, 18].”
BackgroundMixed Adenoneuroendocrine Carcinoma Is a Rare but Important Tumour Found in the Oesophagus
Kadhim, M. M. K., Jespersen, M. L., Pilegaard, H. K., Nordsmark, M., & Villadsen, G. E. (2016) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2016/9542687 · Cited by 17
“According to the “Nordic guidelines for neuroendocrine neoplasms in 2014” [1] and to the European and North American guidelines for neuroendocrine neoplasms [6, 7], cisplatin or carboplatin and etoposide are recommended.”
MethodVanoli, A., Grami, O., Klersy, C., Milanetto, A. C., Albarello, L., Fassan, M., Luchini, C., Grillo, F., Spaggiari, P., Inzani, F. S., et al. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09720-6 · Cited by 17
“Extended author information available on the last page of the article / Published online: 13 May 2022 Endocrine Pathology (2022) 33:274–288”
BackgroundMethodSelf-citationEndoscopic resection of submucosal tumors
Longcroft‐Wheaton, G., & Bhandari, P. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1003366 · Cited by 16
“In 2012, ENETS released an update to their consensus guidelines reflecting the changes in this field [39,40].”
BackgroundOsera, S., Oono, Y., Ikematsu, H., Yano, T., & Kaneko, K. (2015) · Surgical Endoscopy · doi:10.1007/s00464-015-4703-y · Cited by 16
“European guidelines recommended that duodenal carcinoids\10 mm in diameter confined to the submucosa as seen on EUS should be treated with endoscopy in the absence of apparent lymph node invasion and distant metastases [9].”
Luna, I. E., Monrad, N., Binderup, T., Thoegersen, C. B., Hilsted, L., Jensen, C., Federspiel, B., & Knigge, U. (2015) · Neuroendocrinology · doi:10.1159/000441605 · Cited by 16
Self-citationTüzün, A. E., Keskın, O., Yakut, M., Kalkan, Ç., & Soykan, İ. (2013) · Platelets · doi:10.3109/09537104.2013.821607 · Cited by 16
“In this disease, overall survival rates are excellent in which disease-specific survival rate approaches 100% [6].”
BackgroundManagement of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study
Chen, Y., Guo, W., Shi, Y., Su, F., Yu, F., Chen, R., Wang, C., Liu, J., Luo, J., & Tan, H. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-03079-6 · Cited by 18
Kos‐Kudła, B., Ćwikła, J. B., Ruchała, M., Hubalewska–Dydejczyk, A., Jarząb, B., Krajewska, J., & Kamiński, G. (2017) · Współczesna Onkologia · doi:10.5114/wo.2017.68619 · Cited by 15
Zhou, Y., Lu, X., Zheng, K. I., Wang, Q.-W., Chen, J.-N., Zhang, Q., Yan, F., & Li, X. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00565-w · Cited by 15
“Another notable drawback was the inability to classify patients according with the clinical subgroups (Type I, II, III) according with international guidelines [16], where type III tumour showed markedly worse outcome than others.”
BackgroundAnatomic and Functional Imaging of Neuroendocrine Tumors
Morse, B. G., Al‐Toubah, T., & Montilla-Soler, J. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00770-8 · Cited by 15
Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study
Li, X., Shao, L., Lu, X., Yang, Z., Ai, S., Sun, F., Wang, M., Guan, W., & Liu, S. (2021) · BMC Surgery · doi:10.1186/s12893-021-01174-7 · Cited by 15
“European Neuroendocrine Tumor Society (ENETS) guidelines didn’t provide relevant information in the 2012 version [8].”
BackgroundFavorable long‐term outcomes of endoscopic resection for nonampullary duodenal neuroendocrine tumor
Matsueda, K., Kanesaka, T., Kitamura, M., Shichijo, S., Maekawa, A., Yamamoto, S., Takeuchi, Y., Higashino, K., Uedo, N., Michida, T., et al. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15586 · Cited by 15
Clinical features and management of type I gastric carcinoids
Sato, Y. (2014) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-014-0528-9 · Cited by 15
“guidelines have recommended that all TIGCs should be removed whenever possible, although tumor development has not been found to be less favorable in patients with tumors \10 mm left in place [37].”
BackgroundMethodInfluentialUpdated features associated with type 1 gastric carcinoids patients: a single-center study
Lahner, E., Galli, G., Esposito, G., Pilozzi, E., Corleto, V. D., & Annibale, B. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.968859 · Cited by 15
“Diagnosis of T1-GCs was performed when enterochromaffin-like cells’ nodular proliferation was >500 mm in diameter [23] classified according to WHO 2010 criteria [3,4].”
MethodGodat, S., Robert, M., Caillol, F., Bories, E., Pésenti, C., Cassan, C. D., Ratone, J., Poizat, F., & Giovannini, M. F. (2015) · United European Gastroenterology Journal · doi:10.1177/2050640615604774 · Cited by 15
“1%) according to the standard guidelines for NETs.(13) Nine EMRs (27.”
InfluentialWorkup of Gastroenteropancreatic Neuroendocrine Tumors
Dillon, J. S. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.10.002 · Cited by 18
Metadata
- Authors
- Delle Fave, G., Kwekkeboom, D. J., Van Cutsem, E., Rindi, G., Kos-Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., & Ruszniewski, P.
- Affiliations
- Hôpital Louis-Mourier (FR)
- Agostino Gemelli University Polyclinic (IT)
- Copenhagen University Hospital (DK)
- Tohoku University (JP)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Hôpital Beaujon (FR)
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2012
- Volume
- 95
- Issue
- 2
- Pages
- 74-87
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2158048233
- Cited by
- 327
- References
- 138
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 14 · 2023: 27 · 2022: 25 · 2021: 22 · 2020: 22 · 2019: 17 · 2018: 18 · 2017: 22 · 2016: 36 · 2015: 45 · 2014: 27 · 2013: 19 · 2012: 9
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- neuroendocrine tumors, consensus recommendations, clinical management, gastrinoma, pancreatic neuroendocrine tumors
- MeSH terms
- Duodenal Neoplasms, Humans, Stomach Neoplasms, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.